Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 17/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.39 |
| ▸ | CALCA | P06881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278831 | 0.91 | CALCRL (0.46) | CALCRLCYP3A4RAMP1 | |
| SCHEMBL3278823 | 0.91 | CALCRL (0.46) | CALCRLCYP3A4RAMP1 | |
| SCHEMBL3279641 | 0.86 | CALCRL (0.53) | CALCRLCYP3A4CALCA | |
| SCHEMBL3277961 | 0.86 | CALCRL (0.53) | CALCRLCYP3A4 | |
| SCHEMBL3284643 | 0.83 | CALCRL (0.53) | CALCRLCYP3A4CALCA | |
| SCHEMBL6262031 | 0.80 | CALCRL (0.46) | CALCRLCYP3A4 | |
| SCHEMBL6268725 | 0.80 | CALCRL (0.44) | CALCRLCYP3A4CALCA | |
| SCHEMBL13303231 | 0.79 | CALCRL (0.45) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3282456 | 0.79 | CALCRL (0.52) | CALCRLCYP3A4 | |
| SCHEMBL13303229 | 0.79 | CALCRL (0.49) | CALCRLCYP3A4CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| EP-1558601-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2004037811-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | CALCRL 1/4885CYP3A4 2631/4885ALDH1A1 695/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | CALCRL 1/4885CYP3A4 2631/4885ALDH1A1 695/4885 |
| US-20040132716-A1 | CGRP antagonists | OPRL1, HTR1D, CALCA | CALCRL 4/4885CYP3A4 2140/4885ALDH1A1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.